Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Eli Lilly Reveals Positive Outcome From BPH Drug Cialis Study

Eli Lilly and Co. (LLY: Quote) Tuesday said Cialis improved urinary symptoms and erectile dysfunction in a study of the drug in parallel with Tamsulosin in men with signs and symptoms suggestive of Benign Prostatic Hyperplasia. While Tamsulosin improved urinary symptoms, it did not improve erectile function.

Benign prostatic hyperplasia or BPH is a condition where the prostate enlarges, which can cause urinary symptoms. Erectile dysfunction or ED and BPH are conditions that may occur in the same patient. Several studies have shown that many men with ED also experience the symptoms of BPH.

Cialis for daily use is approved to treat ED, the signs and symptoms of BPH, and ED and the signs and symptoms of BPH in men who have both conditions.

Eli Lilly said this was the first Cialis study to show significant improvement in signs and symptoms of BPH after one week and a significant increase in maximum urinary flow rate at 12 weeks. Both treatments significantly improved total International Prostate Symptom Score (IPSS) as early as one week. Maximum urinary flow rate or Qmax increased significantly versus placebo with both Cialis and Tamsulosin.

In the phase III study, published online by European Urology, Cialis improved ED in those men who had both signs and symptoms of BPH and ED. The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and Tamsulosin.

The randomized, double-blind, placebo-controlled, parallel-group, 12-week trial, conducted in 44 urology centers in 10 countries, assessed the efficacy and safety of Cialis 5 mg for daily use in parallel with Tamsulosin 0.4 mg in men aged 45 years and older with signs and symptoms of BPH.

The primary measure was the International Prostate Symptom Score (IPSS), a questionnaire evaluating lower urinary tract symptoms or LUTS occurring during the preceding month where lower scores indicate less severe LUTS.

Cialis improved IPSS total scores by 2.1 through 12 weeks versus placebo. Tamsulosin improved IPSS total scores by 1.5 through 12 weeks versus placebo. The maximum score is 35 with lower scores indicating less severe LUTS.

The IIEF-EF domain, where higher scores indicate better erectile function, improved with Cialis versus placebo but not with tamsulosin versus placebo. The score improved by 4.0 for Cialis while decreasing 0.4 for Tamsulosin.

The proportion of subjects reporting at least one treatment-emergent adverse event was: Cialis 23.4 percent, Tamsulosin 23.8 percent and placebo 20.3 percent.

The study did not directly compare Cialis versus Tamsulosin.

Cialis inhibits an enzyme called phosphodiesterase type 5 (PDE5). By inhibiting PDE5 in the penis, Cialis helps produce vascular relaxation and increases blood flow. PDE5 enzymes are also found in the prostate and bladder.

Tamsulosin hydrochloride was invented and developed by Astellas Pharma Inc (ALPMF.PK) for the treatment of the signs and symptoms of BPH.

LLY is currently trading at $39.59, down $0.06 or 0.14%, on the NYSE. Over the past year, the stock traded in a range of $33.46 - $42.03.

Register
To receive FREE breaking news email alerts for Eli Lilly And Co. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.